Retroviral vectors derived from the amphotropic murine leukaemia virus (aMLV) allow an efficient but unspecific gene transfer into a variety of human cells, followed by integration of the delivered gene construct into the chromosomes. Amphotropic retroviral vectors are therefore used in many clinical ex vivo gene therapy trials. For in vivo gene therapy protocols, targeting entry of retroviral vectors to preselected subpopulations of human cells is an important prerequisite. During the past few years, a series of different targeting strategies have been developed. 1, 2 Among the initial strategies was the host range extension to specific human cells of avian and murine retroviruses. For this purpose, the envelope (Env) proteins of the ecotropic Moloney murine leukaemia virus (MoMLV) or the avian spleen necrosis virus (SNV) had been covalently modified with antibody fragments (scFvs) directed against human cell surface antigens. Although display of a number of different scFvs and growth factors on MoMLV resulted in redirected binding of the vector particles to human cells, cell entry and gene transfer was usually inefficient. [3] [4] [5] However, alternative targeting strategies for MLV like, for example, protease activatable vectors have been developed. 6, 7 In contrast to MoMLV, the host range of SNV particles has been successfully extended to human cells. Here, scFvs specific for human cell surface antigens are covalently linked to the N-terminus of the transmembrane (TM) protein of the SNV Env protein. This scFv-TM targeting molecule is then coexpressed together with the unmodified (wild-type) SNV Env protein in stable packaging cell lines. Previously, SNV derived targeting vectors selective for the carcinoembryonic antigen-related cell surface protein, 8 the transferrin receptor, the Her2/neu antigen or the human stem cell marker CD34 9 have been described. More recently, we generated an SNV vector displaying the T cell specific scFv 7A5 which we selected from a phage display library. The resulting targeting vector allowed the preferential transduction of human lymphoid cells with titers of up to 10 6 IU/ml. 10 Current limitations of the SNV system for a future in vivo gene transfer application in humans include its high sensitivity against human complement. In contrast, MLV vector particles released from human packaging cells are relatively resistant against human serum and have therefore been frequently used in clinical trials. [11] [12] [13] [14] Here we show that human complement resistant vectors targeting human lymphoid cells can be obtained by pseudotyping MLV core particles with SNV targeting envelopes.
The sequence and structure of the cytoplasmic domain (C-tail) of heterologous Env proteins is critical for their incorporation efficiency into MLV core particles, and thus the generation of MLV pseudotypes. We have recently described that the TM protein of the SNV-Env encoded by the expression plasmids pRD134 or pIM29, which are usually used to generate SNV-derived vector particles, possesses an abnormally long C-terminus of in total 70 amino acids. Of these, the C-terminal 36 amino acids are encoded by the plasmid backbone due to the cloning strategy used to generate these plasmids on the basis of a wrong sequence available in the database. 10, 15 In previous studies we have shown that sequence and length of the C-tail of Env proteins may be important for an efficient incorporation into MLV vector particles. [16] [17] [18] Moreover, we have recently shown that the C-tail of the SNV Env protein requires proteolytical processing to activate its fusogenic capacity by cleaving off an R-peptide-like sequence similar to that described for MLV. 10 Based on these observations, two variants of SNV-Env proteins were generated to establish the pseudotyping of MLV derived vectors with SNV-Env protein ( Figure 1 ). By inserting a stop codon behind amino acid 34 of the Ctail in pRD134 plasmid, pRD134 corr was generated thus encoding a TM protein which is 100% identical in the amino acid sequence of its C-tail to that of the closely related avian reticuloendotheliosis virus (REV) 15 ( Figure  1b ). In the second construct a stop codon was inserted behind the putative protease cleavage site (Bobkova and Buchholz, unpublished) to generate an R-peptide free TM protein ( Figure 1c) .
Expression of the three types of Env proteins in 293T cells was then controlled by radioimmunoprecipitation using a monoclonal SNV-TM specific antibody, essentially as previously described. 10 Separation of the precipi-
Figure 1 Schematic representation of the SNV TM protein C-tail variants. The C-terminal domains 3Ј of the putative transmembrane spanning region (C-tails) are shown. They are composed of an N-terminal domain (white box), the putative R-peptide (filled box) and the vector backbone encoded part (grey box) as depicted. The putative R-peptide cleavage signal is labelled in bold letters. (a) Plasmids pRD134 and pIM29 encode the SNV-Env protein with the abnormally long TM C-tails and have been described for the generation of SNV targeting vectors. 25 (b) Plasmid pRD134 corr encodes the Env variant with the corrected C-terminal domain of the TM protein and was constructed by altering codon 36 of the C-tail into a stop codon using PCR and the primer SNV-SacII+: 5Ј-GCCCGCGGATGGACTGTCTCACCACCCTCC-3Ј and SNV-KpnI-: 5Ј-CCGGTACCTCATTGACCTAGGGTATCCATCTCTGTTGG-3Ј). The PCR fragment was inserted into pRD134 via SacII/KpnI. (c) Plasmid pRD134delR was generated by changing codon 21 (proline) of the C-tail (position 2719 of pRD134) into a stop codon using the 'quick-change site directed mutagenesis kit' (Stratagene, La Jolla, CA, USA).
tates on a 12% sodium-dodecyl-sulfate-polyacrylamide gel revealed that all three TM-variants were expressed and migrated according to their predicted molecular weights ( Figure 2 , lanes 1-3). To check for incorporation of the original and the corrected Env proteins into MLV particles, plasmids pRD134 and pRD134 corr were expressed in 293T cells along with the gag/pol genes, encoded by pHIT60 and an MLV packagable lacZ reporter gene (pMFGnlslacZ), respectively. 19 In the presence of the MLV gag/pol proteins, both types of TM proteins appeared as double bands when derived from the cell extracts as well as when prepared from the vector particles (Figure 2, lanes 6-9) . While the upper bands corresponded to the sizes of the unprocessed TM proteins, both of the faster migrating forms corresponded well to the size of the TM ⌬R protein, thus representing the R-peptide-free processed TM-protein (compare lanes 6-9, with lane 3). Notably, the ratios of unprocessed and processed TM proteins were different in cell extracts and vector particles. While the cell-associated TM proteins were mainly in the unprocessed form, the processed form was prominent in virus particles, being in agreement with the hypothesis that R-peptide cleavage occurs upon particle formation. 20 Comparison of lanes 7 and 9 indicates that R-peptide cleavage is more efficient in the TM protein with the corrected C-tail TM corr , while the overall incorporation rate of the TM protein with the long C-tail seems to be higher. However, the enhanced signal intensities in lanes 6 and 7 may, at least in part, also be due to a higher number of methionine residues in TM protein as compared with TM corr . Indeed, the infectivities mediated by both SNV Env proteins were similar (see below).
Figure 2 Incorporation and proteolytic processing of SNV-TM protein in MLV particles. 293T cells grown to subconfluency in six-well dishes were transfected with plasmids encoding the indicated TM protein variants, either individually (lanes 1-3) or in cotransfections together with plasmids pHIT60 and pMFGnlslacZ (lanes 6-9). Untransfected cells served as negative controls (lanes 4, 5
Next, the SNV Env variants were tested for their ability to mediate infectivity of SNV or MLV vector particles on the SNV-permissive D17 cell line. Supernatants from 293T cells, transiently transfected with the Env encoding plasmids together with plasmids pHIT and pMFGnlslacZ, using Lipofectamin (Gibco, Eggenstein, Germany), were collected and used for infection. Titers were determined upon X-gal staining of the transduced cells. All three types of Env proteins mediated transduction at similar efficiencies. The titers of the MLV/SNV pseudotype vectors ranged between 1 × 10 5 IU/ml and 2 × 10 5 IU/ml and were only slightly below those obtained with SNV-derived gag/pol proteins and the corresponding LacZ transfer vector (Table 1) . Thus, neither in the homologous nor in the heterologous situation was a significant difference between the three Env protein variants observed.
Having demonstrated that MLV vector particles can be efficiently and functionally pseudotyped with the SNV Env protein, we established stable producer cells based on the human packaging cell line TelCeB6, which expresses the MLV gag/pol genes and a packagable LacZ reporter gene. 3, 12 TelCeb6 cells were co-transfected with plasmids pIM29 8 encoding the SNV-Env protein and pREP4 for hygromycin selection (Invitrogen, Leek, The Netherlands). Single cell clones were established by hygromycin selection (200 g/ml) and were tested for transduction of D17 cells. After selection, the packaging cell clones MS4 and MS13 were obtained each releasing MLV(SNV)-vector particles with titers of about 10 5 IU/ml as measured by transduction of D17 cells.
A prerequisite for in vivo gene therapy protocols is the resistance of vector particles against inactivation by human serum complement proteins. It was described that retroviral vector particles released by human packaging cells are more resistant against human serum than vector particles derived from non-human packaging cell lines. [11] [12] [13] [14] We therefore compared the resistance of the MLV(SNV)-pseudotype vector particles derived from the packaging cell line MS13 with SNV vector particles derived from the canine packaging cell line DSH-cxl against serum from five healthy human donors. 100 l supernatant from DSH-cxl or MS4 cells (titer 1-5 × 10 5 IU/ml) were preincubated with either 50 l of native or of heat inactivated (1 h, 56°C) serum. After 1 h incubation at 37°C the vector particles were used to transduce 1 × 10 5 D17 cells. X-gal stain was performed 48 h after transduction. The survival rate was calculated by normalising the titers obtained after preincubation with the native sera to those obtained with the inactivated sera.
The results in Figure 3 show that the MLV(SNV) pseudotype vectors were on average 20 times more resistant than SNV-vectors towards human serum. While the SNV-vectors were almost completely inactivated (mean survival rate of 3.5%) the survival rate of the pseudotype vectors ranged between 30% (serum No. 5) and 95% (serum No. 4).
In the next step we aimed at generating MLV(SNV) pseudotype vectors that are selective for human T cells. For this purpose, MS4-cells were transfected with the plasmid pTC53-7A5neo, which encodes the 7A5-TM fusion protein and a neomycin resistance gene. The latter was derived from plasmid pcDNA3 (Invitrogen) and exchanged against the zeocin resistance gene in plasmid pTC53-7A5zeo 10 via NdeI sites using a standard PCR with primers NEO-NDE(+): 5Ј-GGAATTCCATATG CCAGGCAGGCAGAAGTATGCAAAGC-3Ј and NEO-NDE(−): 5Ј-GGAATTCCATATGGGACAAACCACAAC-TAGAATGCAGTG-3Ј (NdeI restriction sites are underlined). After G418 selection (800 g/ml; Sigma, Germany) single cell clones were obtained and tested for transduction of the human T cell line A3.01. The cell clone MS4-7A5 produced vector particles which were most efficient in transduction. It was therefore expanded and the secreted vector particles were further characterised. To demonstrate the T cell selectivity of MLV(SNV-7A5) vector particles supernatants derived from MS4 cells and MS4-7A5 cells were tested in parallel for transduction of a panel of different cell lines.
On D17 cells, which served as positive control, the MLV(SNV-7A5) vector reproducibly gave about 10-fold higher titres than the MLV(SNV) vector stock (Figure 4 ). This was surprising as both packaging cell lines should only differ by the presence of the 7A5-TM expression construct. Western blot analysis of concentrated vector particles confirmed that particles released from the MS4-7A5 cells contained, besides the 7A5-TM protein, significantly higher amounts of the unmodified TM protein than particles released from MS4 cells (data not shown). Although the reason for this discrepancy is unclear it explains the higher titres of MLV(SNV-7A5) particles on D17 cells. In the human cell lines the ML(SNV-7A5) vector was clearly selective for T cell lines. While there was only background activity on HeLa and TE671 cells (Ͻ10 IU/ml) Molt 4-8 and A3.01 cells were efficiently transduced with titres of up to 10 5 IU/ml (Figure 4 ). In contrast, vector particles containing the SNV-Env only were not infectious for any of the human cell lines.
Our data demonstrate that the SNV Env protein becomes readily incorporated into MLV particles. The resulting MLV(SNV) particles infected SNV permissive cell lines with the same efficiency as SNV particles. The SNV Env protein thus adds to a list of now about 10 different retroviral envelope proteins that have been incorporated into MLV core particles, although with different efficiencies. 21 Env proteins that were efficiently incorporated were all derived from C-type retroviruses, namely gibbon ape leukaemia virus (GALV), RD114, or MLV10A1. The infectivities of the corresponding pseudotype particles were similar to those of the parental viruses. Notably, the C-tails of all of these Env proteins include a similar number of amino acids as that of the MLV Env protein. In contrast, the extraordinary long Ctails (about 150 amino acids) of lentiviral Env proteins required substantial truncation to about 10 amino acids before infectious pseudotypes were obtained. 16, 17, 22 It is therefore surprising that infectivity of the MLV(SNV) pseudotype vector containing the SNV Env variant with the long C-tail of 70 amino acids was as high as that of the pseudotype vectors containing variants with shorter C-tails. Obviously, other factors in addition to length of the C-tail are critical for efficient pseudotype formation. This is also the case for the foamy virus Env protein which has a short C-tail of only 13 amino acids, yet incorporation efficiency into MLV cores and infectivity of the pseudotypes were shown to be low. 23 For Env proteins from C-type viruses, although so far only demonstrated for MLV and GALV, 20, 24 efficient cleavage of the R-peptide may be critical for the infectivity of the pseudotype particles. In agreement with this hypothesis, Western blot analysis of the TM proteins in cell extracts and pseudotype particles revealed that the MLV protease was able to process the SNV TM protein C-tail upon particle forGene Therapy mation. Thus, protease activity and cleavage signals in the C-tails must be conserved between SNV and MLV.
The efficient pseudotype formation allowed us to coincorporate the 7A5-TM targeting molecule along with the wild-type SNV Env protein into MLV core particles. For production of the MLV(SNV-7A5) vector, the generation of a stable packaging cell clone selected for release of T cell tropic vector particles was essential. Transient transfections of 293T cells as used for the generation of the MLV(SNV) particles did not allow generation of functional MLV(SNV-7A5) or SNV-7A5 vectors (Merten and Buchholz, unpublished). We therefore suspect that the SNV targeting system requires a well-defined ratio of the amounts of wild-type Env protein and 7A5-TM protein.
Adjustment of this critical ratio might occur during selection of the packaging cell clones. Indeed, Western blot analysis showed a significantly higher amount of TM protein, ie wild-type Env protein, incorporated into MLV(SNV-7A5) particles released from the MS4-7A5 cells than the MLV(SNV) particles released from the parental MS4 cells (data not shown). In agreement with the Western blot analysis, the MLV(SNV-7A5) particles were about 10-fold more infectious on D17 cells than the MLV(SNV) pseudotypes. However, further experiments will be required to understand the necessity for clonal selection of packaging cell lines in the SNV targeting system.
The MLV(SNV-7A5)-pseudotype vector revealed the same T cell-restricted tropism as the SNV-7A5 vector. 10 However, in contrast to the latter the pseudotype vector was generated using the human packaging cell line TelCeb6 and was therefore largely resistant against inactivation by human serum. This is at least in part remarkable as MLV vector particles carrying the homologous amphotropic Env protein were shown to be human complement sensitive when released from TelCeb6 cells. 13 Thus, in this respect, the SNV Env protein seems to be more related to the RD114 Env which in contrast to the MLV Env protein mediated complement resistance upon expression in TelCeb6 cells. 12 Overall, our results demonstrate that the SNV targeting principle can be successfully transferred to MLV thereby offering new possibilities for the design of retroviral targeting vectors. Due to their complement resistance the MLV(SNV)-pseudotype vectors described here are more suitable for in vivo applications than conventional SNVvectors derived from the only available canine-derived packaging cell line DSH-cxl 25 and thus will substantially contribute to retrovirus-based somatic gene therapy.
